Published online Jan 6, 2023. doi: 10.12998/wjcc.v11.i1.92
Peer-review started: September 28, 2022
First decision: November 4, 2022
Revised: November 10, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 6, 2023
Papillary thyroid cancer is a highly heterogeneous disease and therefore molecular markers need to be established to predict its prognosis.
The present study aims to explore novel markers consisting of microRNA (miRNA)-associated signatures for papillary thyroid cancer (PTC) prognostication.
To establish a practical tool has satisfying potential in stratifying PTC patients and individualized therapy to avoid overtreatment or inadequate treatment.
In this study, a panel of four miRNAs is generated as a prognostic signature, which is then tested in PTC patients.
The panel of four miRNAs could reliably distinguished PTC patients from high and low risk with a significant difference in the overall survival.
More intensive treatment and closer follow-ups for high-risk PTC patients are recommended.
Our prognostic signature contributed to individualized therapy to avoid overtreatment or inadequate treatment.